Try our Advanced Search for more refined results
Securities and Exchange Commission v. Aveo Pharmaceuticals, Inc. et al
Case Number:
1:16-cv-10607
Court:
Nature of Suit:
Judge:
Firms
Government Agencies
-
April 23, 2019
Ex-Aveo CFO Says Securities Fraud Verdict Should Be Tossed
The former chief financial officer of Aveo Pharmaceuticals asked a Massachusetts federal judge on Monday to erase the verdict against him for civil securities violations, saying it was based on a misreading of the law.
-
March 25, 2019
Ex-Aveo CFO Gets 2-Year Corporate Bar For Duping Investors
A Boston federal judge has barred the former chief financial officer of Aveo Pharmaceuticals from serving as an officer and director of a public company for two years after a jury found him liable for civil securities violations in November, saying he led the scheme but didn't deserve the lifetime ban the government sought.
-
November 20, 2018
Ex-Aveo CFO Found Liable For Misleading Investors
A Massachusetts federal jury found the former chief financial officer of Aveo Pharmaceuticals liable for civil securities fraud in Boston on Tuesday, saying he misled investors by failing to tell them the U.S. Food and Drug Administration had recommended a second clinical trial for Aveo's flagship kidney cancer drug, Tivo.
-
November 14, 2018
Aveo CFO Testifies He Had Support For Disclosure Decisions
Lawyers, board members and company officials all signed off on a decision by Aveo Pharmaceuticals to not tell investors about a recommendation for a new clinical trial, Aveo's former chief financial officer testified Wednesday as the defendant in a civil securities fraud case in Massachusetts federal court.
-
November 13, 2018
Aveo Withheld FDA Rec From Investors, Ex-CFO Testifies
Defendant David Johnston took the witness stand Tuesday in Boston federal court and told jurors the government was correct that his former company, Aveo Pharmaceuticals Inc., chose not to tell investors about the U.S. Food and Drug Administration's recommendation for a new clinical trial for its flagship kidney cancer drug, Tivo.
-
November 06, 2018
Aveo CFO Told Investors 'Half The Story,' Jury Hears
The former chief financial officer for Aveo Pharmaceuticals "hid" from investors that a government agency had recommended a new clinical trial for the company's prize kidney cancer drug, an attorney for the U.S. Securities and Exchange Commission told a jury Tuesday in Boston federal court.
-
November 05, 2018
Jury Picked For Ex-Drug Co. CFO's Securities Fraud Trial
A jury of seven women and five men was seated Monday in Boston for a two-week civil case to determine whether Aveo Pharmaceuticals' former chief financial officer misled investors about the likelihood of a cancer drug approval by concealing that the U.S. Food and Drug Administration had recommended a second clinical trial.
-
November 01, 2018
Aveo Stock Plunge Fair Game When Ex-CFO Stands Trial
The government can tell a jury about how the stock price of an Aveo Pharmaceuticals cancer drug plummeted 31 percent after the public learned the U.S. Food and Drug Administration had requested a second round of testing, a Massachusetts federal judge ruled Thursday as former Aveo CFO David Johnston prepares to stand trial next week.
-
April 20, 2018
Ex-Aveo CFO Denied Quick Win In SEC's Cancer Drug Suit
A Massachusetts federal judge on Thursday denied a summary judgment bid from the only former Aveo Pharmaceuticals Inc. executive still fighting the U.S. Securities and Exchange Commission's claims that the company misled investors about the likelihood of approval for its premier cancer drug.
-
February 09, 2018
Former Aveo Chief Medical Officer Ordered To Pay SEC $50K
A federal magistrate judge in Boston on Friday ordered the former chief medical officer at Aveo Pharmaceuticals Inc. to pay a $50,000 civil penalty to the U.S. Securities and Exchange Commission, one-third of what the agency sought, to end claims that he misled investors in a 2012 conference call.